Marijn E Dekkers
CIK 1216068 · Chief Executive Officer · last filed 2024-08-05
Marijn E Dekkers is a Chief Executive Officer who has filed 87 SEC Form 4 insider transactions across 8 companies since 2007. Across all open-market trades the lifetime net is −$135.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $75.4M across reported positions. 27 SEC filings were submitted jointly with GENERAL ELECTRIC CO.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TMO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
41 FARNSWORTH STREET
BOSTON, MA 02210
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Director | 5,901,844 | $0.01 | $37.2K | -$2.27M | 8 | 2024-06-14 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 444,609 | $44.96 | $19.99M | -$6.89M | 5 | 2024-06-07 |
| QSI | Director | 650,000 | $1.46 | $949.0K | $0 | 2 | 2022-05-13 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | — | $18.07 | — | $0 | 1 | 2021-06-14 |
| QTRX | Director | 11,031 | $2.83 | $31.2K | -$4.63M | 10 | 2021-06-08 |
| GE | Director | 8,226 | $288.43 | $2.37M | $1.16M | 25 | 2018-04-02 |
| TMO | Chief Executive Officer | 102,814 | $684.89 | $70.42M | -$123.13M | 29 | 2009-08-18 |
| BIIB | Director | 6,595 | $252.26 | $1.66M | $0 | 3 | 2009-06-05 |
Recent Filings
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-05 | — | Disp (D) | −444,609 | $0 | |
| 2024-06-14 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Exer (M) | +105,263 | $0 | EDGAR |
| 2024-06-07 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +10,461 | $0 | EDGAR |
| 2024-05-20 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −265,000 | -$220.0K | EDGAR |
| 2024-05-14 | DNA | Notice (144) | −1,727,056 | -$1.61M | EDGAR |
| 2024-05-14 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Sell (S) | −1,727,056 | -$1.61M | EDGAR |
| 2023-07-28 | QSI | Notice (144) | −29,049 | -$95.3K | EDGAR |
| 2023-07-19 | QSI | Notice (144) | −30,831 | -$112.2K | EDGAR |
| 2023-06-21 | Ginkgo Bioworks Holdings, Inc. (DNA.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-20 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Sell (S) | −200,000 | -$6.89M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.